Pembrolizumab biosimilar (Hualan Genetic Engineering)

帕博利珠单抗生物类似药 (华兰基因工程)

Report date: 2026/02/26 20:00:22

Base Information

Drug NamePembrolizumab biosimilar (Hualan Genetic Engineering)
Drug Alias NameN/A
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionProgrammed cell death protein 1 blockers
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsMicrosatellite instability-high cancerMismatch Repair Deficient CancerUterine Cervical Neoplasms +[13] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHualan Ankang Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHualan Ankang Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsMicrosatellite instability-high cancerMismatch Repair Deficient CancerUterine Cervical Neoplasms +[13] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A